The invention is generally directed to the treatment of uterine disorders by detecting and regulating blood flow through one or both of the patient's uterine arteries.
Hysterectomy (surgical removal of the uterus) is performed on approximately 600,000 women annually in the United States. Hysterectomy is often the therapeutic choice for the treatment of uterine cancer, adenomyosis, menorrhagia, prolapse, dysfunctional uterine bleeding (abnormal menstrual bleeding that has no discrete anatomic explanation such as a tumor or growth), and muscular tumors of the uterus, known as leimyoma or uterine fibroids.
However, hysterectomy is a drastic treatment, having many undesirable characteristics. Thus, any method which can approximate the therapeutic result of a hysterectomy without removing the uterus would be a significant improvement in this field. Newer treatment methods have been developed for some diseases which may spare these women a hysterectomy.
In 1995, it was demonstrated that uterine fibroids could be treated without hysterectomy using a non-surgical therapy, specifically comprising bilateral intraluminal occlusion of the uterine arteries (Ravina et al., “Arterial Embolization to Treat Uterine Myomata”, Lancet Sep. 9, 1995; Vol. 346; pp. 671-672, incorporated in its entirety herein). This technique is known as “uterine artery embolization”. In this technique, uterine arteries are accessed via a transvascular route from a common femoral artery into the left and right uterine arteries by means of an intravascular catheter and embolic material, such as small metallic coils, polyvinyl alcohol particulate and the like, is delivered through the catheter to the uterine arteries which quickly become occluded.
The uterus has a dual (or redundant) blood supply, the primary blood supply being from the bilateral uterine arteries, and the secondary blood supply from the bilateral ovarian arteries. Consequently, when both uterine arteries are occluded, i.e. bilateral vessel occlusion, the uterus and the fibroids contained within the uterus are both deprived of their blood supply. However, as demonstrated by Ravina et al., the ischemic effects on the fibroid is greater than the effect on the uterus. In most instances, the fibroid withers and ceases to cause clinical symptoms.
However, many physicians do not possess the training or equipment necessary to perform catheter-based uterine artery embolization under radiologic direction. Accordingly, there are substantially fewer uterine artery embolizations performed, worldwide, each year than hysterectomies for symptomatic uterine fibroids.
Recently, fibroid treatment procedures have been described wherein the uterine arteries are temporarily occluded by an intravaginal device which is non-invasively pressed against the patient's vaginal fornix and clamped or otherwise pressed against tissue bundle with the patient's uterine artery being within the bundle. Pressure on the tissue occludes the underlying uterine artery. While these procedures have shown much promise the clamps were for the most part required to be left in the patient which restricted the patient to a hospital or a clinical setting for the duration of the treatment.
What is needed, therefore, are devices and methods to detect blood vessels and blood flow in blood vessels, and devices and methods to occlude blood flow in blood vessels such as the uterine arteries that can be used by physicians with limited training and equipment and allows the patient to quickly return to normal activity.
The invention is directed to an intra-vaginal staple for occluding a female patient's uterine artery by means of a relatively non-invasive intravaginal delivery device and to a system and a procedure for installing the staple.
An intravaginal staple embodying features of the invention includes an occlusion bar which has a pressure applying surface configured to apply pressure against the exterior of the patient's uterine cervix or against the patient's vaginal fornix with sufficient pressure to occlude an underlying uterine artery. The intravaginal staple also has at least one leg which extends distally away from the pressure applying surface of the occlusion bar and which is configured to penetrate through the wall of the patient's vaginal fornix until at least the distal portion of the leg or legs advance into the patient's uterine wall or other tissue. The leg or legs are configured to secure the staple with the occlusion bar applying sufficient pressure against the patient's vaginal fornix to ensure at least partial occlusion of an underlying uterine artery.
At least part of the intravaginal staple should be formed of bioabsorbable material so that the occlusion bar occludes the uterine artery for a selected time period for the therapeutic affects desired and then the bioabsorbable portion of the staple breaks down which in turn releases the pressure applied by the occlusion bar. The staple legs, the protrusions on one or more of the staple legs, the occlusion bar, or the junction between the legs and the occlusion bar may be formed of suitable bioabsorbable material which is absorbed at a suitable rate for the desired break down of the staple.
In one embodiment of the invention, the staple or the staple delivery system is provided with a blood flow sensor is be applied to a portion of a vaginal wall to detect and/or locate and/or monitor the occlusion of the underlying uterine artery. The wall of the patient's vaginal fornix may be distended by an staple deployment so as to more closely approach the underlying uterine artery. Such an approach may aided by applying tension to the uterus e.g., by pulling on the uterine cervix by any suitable device or implement such as a tenaculum. However, other instruments such as forceps, suction devices, and the like may be employed to pull on the uterine cervix.
A suitable staple delivery or deployment system embodying features of the invention may include an elongated handle having an operative proximal end configured to extend out of a patient to facilitate manual manipulation and an operating distal end which has a staple delivery mechanism which is configured to engaged and apply a staple assembly to the patient's uterine artery. The staple delivery mechanism has a recess for receiving a staple or staple assembly and a driving member or piston in the recess configured to drive the staple or staple assembly into the patient's tissue. The piston may be driven by mechanical, hydraulic or electromechanical means.
Preferably, the staple deployment system is a clamp-type instrument having a pair of elongated handles, with a staple deployment mechanism as described above on each distal end of the handles and a finger grip at each proximal end of the handles. The handles are preferably pivotally connected to facilitate adjustment of the spacing between the staple deployment mechanisms on the distal ends for proper placement of the staples when they are deployed. The handles are configured so the finger grips on the proximal ends of the handles extend out of the patient when the staple deployment mechanism is in position for staple deployment.
An alternative staple assembly includes a generally U-shaped staple member with an occlusion bar having a bore at each end which slidably received the legs of the staple member. The pressure applying surface of the occlusion bar may be provided with a blood flow sensor to ensure proper placement of the bar during deployment.
The staple deployment mechanism or the staple assembly itself is preferably provided with a blood flow sensor for locating the uterine artery to be occluded and monitoring blood flow through the artery after it has been occluded by the staple. The sensor may sense sound, pressure, strain, stress, chemical entity, electromagnetic radiation and the like, and may be a combination of such sensors. A preferred sensor is a Doppler ultrasound sensor. The blood flow sensor is preferably mounted to the face of a tissue-contacting surface of the staple deployment mechanism, such as adjacent to the recess which receives the staple. The sensor should be positioned between the legs of the staple so that the located uterine artery is centrally disposed between the staple legs when the staple is deployed. This ensures that the legs do not penetrate into the arterial wall. Ultrasound energy useful for sensing a location of a blood vessel or of blood flow in a blood vessel has a frequency of less than about 20 MegaHertz (MHz), such as between about 5 MHz and about 19 MHz, and preferably between about 6 MHz and about 10 MHz. In commercially available Doppler sensors the frequency is typically about 8 MHz. For sensors based on electromagnetic (EM) energy useful for sensing a location of a blood vessel or of blood flow in a blood vessel, the EM energy should have a wavelength of about 500 nanometers (nm) to about 2000 nm, preferably about 700 nm to about 1000 nm.
A method for occluding a uterine artery which embodies features of the invention include advancing the staple deployment system through the patient's vaginal canal until each of the staple deployment mechanisms are on adjacent sides of the patient's uterine cervix. The leading edges of the deployment mechanisms are pressed against the wall of the vaginal fornix on each side of the cervical os and the spacing therebetween is adjusted to ensure the staple will be deployed at the proper location. Adjustment of the positions of the staple deployment mechanisms on the distal ends of the handles allows the blood flow sensors on the mechanisms to locate the uterine artery which is a short distance from the surface of the vaginal fornix. With the deployment mechanisms adjacent to the target blood vessels, the leading edges of the deployment mechanisms can be pressed against the patient's vaginal fornix to compress tissue thereof and thereby occlude the underlying uterine arteries. The uterine arteries are located with the blood flow sensors on the leading edges of the staple deployment mechanism. Preferably, tension is applied to the uterine cervix with a grasping implement, such as a tenaculum, (e.g., by pulling on the uterine cervix) while applying force or pressure to a vaginal wall to occlude a uterine artery.
The invention allows for the non-surgical location and occlusion of blood vessels such as the uterine artery, providing effective therapeutic treatment. Importantly, the present invention allows for the occlusion of a female patient's uterine artery without the need for radiographic equipment or for extensive training in the use of radiographic techniques. The devices and methods are simple and readily used for treating uterine fibroids, dysfunctional uterine bleeding (DUB), adenomyosis, post-partum hemorrhage, and other uterine disorders or conditions which may be treated by uterine artery occlusion.
These and other advantages will become more apparent from the following detailed description when taken in conjunction with the accompanying exemplary drawings.
a-2d are various transverse cross-sections taken along the lines 2-2 in
a-3d are various transverse cross-sections taken along the lines 3-3 in
The occlusion bar 11 and the legs 12 and 13 may have a variety of transverse cross-sectional shapes as illustrated in
The staple delivery mechanism 25, which is shown schematically in more detail in
The staple receptor 33 is provided with a blood flow sensor 37 on the upper or leading surface 38 adjacent to the slot opening 36 to facilitate location of the patient's uterine artery as the staple delivery mechanism 25 is pressed against the patient's vaginal fornix during staple deployment. The preferred blood flow sensor 37 is a Doppler ultrasonic fluid flow sensing system. The sensor location on the leading surface 38 allows the operator to more easily guide the staple delivery system 21 to an appropriate location of the patient's target uterine artery. Sensor 36 is provided with a signal and/or energy transmission cable 39 which is operatively connected to sensor control device (not shown). Cable 39 may be an insulated wire, plurality of wires, optical fiber, waveguide, or other connection effective to carry signals and/or energy or power to and/or from the sensor 36.
Blood flow sensor 36 may be a passive sensor which is configured to detect intrinsic signals indicating the presence of a blood vessel (i.e., a sound sensor, a motion sensor, a pH sensor, or other sensor configured to detect a physical, chemical, electrical, or physiological indication of the location of a blood vessel). In other embodiments, the blood flow sensor 36 may be an active sensor, configured to emit energy or a signal, and configured to detect signals in response to, or derived from, the emitted energy or signal indicating the presence of a blood vessel. The operation of a sensor may be aided by an energy source such as a sensor control device. Suitable ultrasonic systems for blood flow detection include the MedaSonics® CardioBeat® Blood Flow Doppler with Integrated Speaker (Cooper Surgical, Inc., Trumbull Conn. 06611)). Other commercially available Doppler ultrasound sensors suitable for use in the present invention include the Koven model ES 100X MiniDop VRP-8 probe (St. Louis, Mo.) and the DWUNeuro Scan Medical Systems' Multi-Dop B+ system (Sterling, Va.).
As best shown in
Closure of a blood vessel, which may be partial or total, is effected by pressure applied through the wall of the patient's vaginal fornix by the occluding bar of the staple. Sufficient pressure or force is applied to the tissue of the vaginal wall by the occluding bar to compress and to at least partially occlude the underlying uterine artery. The blood flow sensor for detecting or locating the uterine artery should be disposed on the leading surface of the staple deployment mechanism and generally should be perpendicular to the tissue-contacting surface of the bar.
The staple 10 is retained with the occluding bar 11 applying pressure to occlude the uterine artery for about 0.5 to about 48 hours, preferably about 1 to about 24 hours for effective therapeutic treatment of a uterine disorder, e.g. for fibroids, PPH, DUB and the like. Sufficient bioabsorption has occurred by this time so the staple 10 begins to disintegrate at selected locations (16-19) thereby releasing the occluding pressure applied by the occluding bar 11 to the uterine artery 41. Blood flow sensor 36, which is effective to locate uterine artery 41 by detecting blood flow, may also be utilized to monitor blood flow through the uterine artery to detect the onset of occlusion and the reestablishment of blood flow through the artery. A strand 20 may be utilized to aid in removing all of parts of the staple 10.
An alternative staple assembly 50 is illustrated in
The uterine artery staple embodying features of the invention may be made from any suitable material or combination of materials, including metals such as stainless steel and superelastic shape memory alloys such as nickel-titanium alloys having a stable austenite phase at body temperature, high strength plastics, ceramics, and other materials known in the art. Biocompatible polymers such as polycarbonate, polysulfone, polyester, polyacetal and a variety of fluoropolymers can be suitable for a variety of embodiments of the invention. The device or system may be designed for single use (disposable) or may be sterilizable and capable of multiple use. The bioabsorbable portion of the staple may be formed of bioabsorbable polymeric materials such a PLA, PGA, polycaprolactone, and copolymers of these materials with polyethylene glycol or other hydrophilic agents.
While particular forms of the invention have been illustrated and described, it will be apparent that various modifications can be made to the invention and that individual features shown in one embodiment can be combined with any or all the features of another embodiment described herein. Accordingly, it is not intended that the invention be limited to the specific embodiments illustrated. This invention should be defined by the scope of the appended claims as broadly as the prior art will permit. Terms such as “element”, “member”, “device”, “section”, “portion”, “means”, “steps” and words of similar import when used herein in the appended claims shall not be construed as invoking the provisions of 35 U.S.C. §112(6) unless the claims expressly use the term “means” followed by a particular function without providing specific structure or “step” followed by a particular function without providing specific action.